STOCK TITAN
  1. Home
  2. Sec-filings
  3. KPTI
  4. [Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity

KPTI reports 43,650 RSUs grant; Cheng now holds 79,506 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Karyopharm Therapeutics (KPTI) reported an executive equity award on a Form 4. EVP & Chief Commercial Officer Sohanya Cheng received 43,650 restricted stock units (RSUs) on 10/15/2025 at $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, Ms. Cheng beneficially owns 79,506 shares directly.

Positive

  • None.

Negative

  • None.

Insights

Routine executive RSU grant with time-based vesting.

Karyopharm Therapeutics disclosed a grant of 43,650 RSUs to EVP & Chief Commercial Officer Sohanya Cheng on October 15, 2025. RSUs convert one-for-one into common shares and carry no exercise price, aligning compensation with share value.

The award vests 100% on December 31, 2026, indicating a time-based retention structure. After this transaction, Ms. Cheng’s directly beneficially owned shares are 79,506, as reported.

This is a standard equity incentive under the company’s 2022 Equity Incentive Plan, as amended. Actual share delivery depends on vesting; dilution impact, if any, would be consistent with plan terms.

Insider Cheng Sohanya Roshan
Role EVP & Chief Commercial Officer
Type Security Shares Price Value
Grant/Award Common Stock 43,650 $0.00 --
Holdings After Transaction: Common Stock — 79,506 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cheng Sohanya Roshan
(Last) (First) (Middle)
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
(Street)
NEWTON MA 02459
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 A 43,650(1) A $0 79,506 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.
/s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did KPTI disclose in this Form 4?

An award of 43,650 RSUs to EVP & Chief Commercial Officer Sohanya Cheng on 10/15/2025.

When do the RSUs for KPTI’s executive vest?

They vest 100% on December 31, 2026.

How do the RSUs convert at Karyopharm (KPTI)?

They convert into common stock on a one-for-one basis.

How many KPTI shares are beneficially owned after the transaction?

79,506 shares are beneficially owned directly after the reported transaction.

Under which plan were the RSUs granted at KPTI?

Under the 2022 Equity Incentive Plan, as amended.

What was the price reported for the RSU acquisition?

The RSUs were reported at $0 per unit as typical for awards.